(CercleFinance.com) – Theranexus recorded a sharp increase on Friday on the Paris Stock Exchange following the presentation of interim results considered ‘very encouraging’ in the treatment of Batten disease.
At 11:15 a.m., the biopharmaceutical company’s action jumped more than 8%, while the CAC Mid & Small index rose 1.4% at the same time.
The interim results of its phase 1/2 study notably showed an absence of notable progression of motor symptoms after 12 months of treatment in the six patients followed, all aged at least 17 years.
For Professor Gary Clark, of Texas Children’s Hospital in Houston, the principal investigator of the study, this is an ‘unprecedented’ result in the indication.
At Theranexus, we emphasize that these results of effectiveness and tolerance after 12 months of treatment confirm those already obtained at six months, which were announced in mid-June.
Juvenile Batten disease is a rare and fatal genetic disorder of the nervous system for which there is currently no treatment.
The first symptom of the juvenile form, a progressive loss of vision, appears between the ages of four and six years, before the appearance of cognitive disorders, behavioral problems and motor difficulties.
This disease is always fatal – usually in late adolescence or early adulthood.
In a press release published yesterday evening, Theranexus reported proforma cash flow of 7.8 million euros following the capital increase completed in July, which gives it financial visibility of at least 12 months.